Ankylosing spondylitis (Q54165668)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17448825%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

Ankylosing spondylitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17448825%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Jürgen Braun

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17448825%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Joachim Sieper

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17448825%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

language of work or name

English

0 references

publication date

1 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17448825%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17448825%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

369

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17448825%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

9570

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17448825%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

1379-1390

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17448825%20AND%20SRC:MED&resulttype=core&format=json

Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Epidemiology of HLA-B27 and Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Incidence and prevalence of ankylosing spondylitis in Northern Norway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Risk factors for functional limitations in patients with long-standing ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

The early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Classification of inflammatory arthritis by enthesitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Determinants of hyperkyphosis in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Phenotypic diversity is not determined by independent genetic factors in familial spondylarthropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Two major spondylarthropathy phenotypes are distinguished by pattern analysis in multiplex families

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

The natural disease course of ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

The outcome of ankylosing spondylitis: a study of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Susceptibility to ankylosing spondylitis in twins the role of genes, HLA, and the environment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Ankylosing spondylitis and HL-A 27.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Report on the Fourth International Workshop on Reactive Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Yersinia antigens in synovial-fluid cells from patients with reactive arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Long-term prognosis of reactive salmonella arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

The histopathology of ankylosing spondylitis: are there unifying hypotheses?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Animal models of inflammatory spinal and sacroiliac joint diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

A longitudinal study on an autoimmune murine model of ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Cellular immunity to the G1 domain of cartilage proteoglycan aggrecan is enhanced in patients with rheumatoid arthritis but only after removal of keratan sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Pathogenesis of square bodies in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Rheumatic diseases: the effects of inflammation on bone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Effects of cyclooxygenase inhibition on bone, tendon, and ligament healing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Cox-2: Where are we in 2003? - The role of cyclooxygenase-2 in bone repair

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

The risk of developing ankylosing spondylitis in HLA-B27 positive individuals: a family and population study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Cytokine gene polymorphisms relevant for the spondyloarthropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Genetic studies in familial ankylosing spondylitis susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Significant linkage to spondyloarthropathy on 9q31-34

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

The X‐chromosome and susceptibility to ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

A locus on chromosome 9p predisposes to a specific disease manifestation, acute anterior uveitis, in ankylosing spondylitis, a genetically complex, multisystem, inflammatory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Role ofNOD2 variants in spondylarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Is disease severity in ankylosing spondylitis genetically determined?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Ankylosing spondylitis. Clinical features

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

How to diagnose axial spondyloarthritis early

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Refining clinical diagnosis with likelihood ratios

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Inflammatory back pain in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Clinical History as a Screening Test for Ankylosing Spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Radiologic diagnosis and pathology of the spondyloarthropathies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back pain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

ASAS/EULAR recommendations for the management of ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Conventional treatments for ankylosing spondylitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Medication toxicity among patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Sulfasalazine for ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Six months open label trial of leflunomide in active ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Treatment of active ankylosing spondylitis with pamidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

One-year open-label trial of thalidomide in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Open label trial of anakinra in active ankylosing spondylitis over 24 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960635-7

7 January 2021

10.1016/S0140-6736(07)60635-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17448825%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference